Keyphrases
Ability to Pay
12%
Active Participation
10%
Advanced Healthcare
12%
Anti-CTLA-4
12%
Anti-PD-1
12%
Antiangiogenic Agents
10%
Aurora
10%
Bethesda
12%
Bevacizumab
38%
Biotechnology Firms
10%
Brain Tumor
83%
Brain Tumor Patients
12%
Cancer Center
41%
Cancer Institute
10%
Cardiology
10%
Cedar
12%
Center of Excellence
10%
Central Nervous System Tumors
12%
Challenging Patients
12%
Cleveland Clinic
12%
Clinical Care
20%
Clinical Centers
10%
Clinical Oncology
12%
Clinical Patients
10%
Clinical Program
25%
Clinical Research
83%
Clinical Support
16%
Clinical Teams
12%
Clinical Trials
70%
CNS Malignancies
12%
CNS Tumors
25%
Collaborative Interaction
12%
Collaborative Research
10%
Columbia University
10%
Complex Patients
12%
Dallas
10%
Data Manager
8%
Endocrinology
10%
Factorial Design
10%
Fellowship Training
10%
Genetic Features
10%
George Washington
12%
Gilbert
51%
Glioblastoma
8%
Health Systems
20%
Healthcare Research
10%
Henry Ford
12%
Hospital Center
12%
Immune Checkpoint Inhibitors
21%
Immune Competence
12%
Immune Response
10%
Immunological Surveillance
12%
Improved Survival
6%
Ipilimumab
17%
Jeffreys
6%
Johns Hopkins
20%
Local Centers
12%
Mayo Clinic
10%
Medical Center
62%
Medical Oncology
10%
Medical University
10%
Methodist
12%
Molecular Information
12%
Molecular Parameters
12%
Molecular Tumor Board
12%
Morphological Characteristics
12%
Multidisciplinary Tumor Board
12%
National Consortium
12%
National Institutes of Health
10%
Neuro-oncology
66%
Neurocognitive Decline
12%
Neurology
10%
Neuroradiology
12%
Neurosurgeon
10%
Neurosurgery
12%
Neurosurgical Practice
12%
New England Journal of Medicine
12%
Newly Diagnosed Glioblastoma
25%
NHLBI
10%
NINDS
10%
Nivolumab
17%
Northwestern University
10%
Ohio State University
12%
Oncologists
20%
Oncology
10%
Oncology nurse Practitioner
8%
Oncology Practice
12%
Oncology Service
10%
Ophthalmology
12%
Palliation
12%
Partial List
12%
Pathology Review
21%
Patient Accrual
10%
Patient Allocation
12%
Patient Care
10%
Patient Information
12%
Patient Referral
25%
Patient Tumor
12%
Peripheral Blood Mononuclear Cells
12%
Pharmaceutical Biotechnology
12%
Placebo-controlled
12%
Plenary Session
12%
Practice Groups
12%
Primary Brain Tumor
10%
Psychiatry
20%
Quality of Life
10%
Radiation Oncologist
12%
Radiation Oncology
10%
Randomized Design
12%
Randomized Phase III Trial
12%
Randomized Placebo-controlled Trial
6%
Reactivity Monitoring
12%
Rehabilitation Medicine
25%
Research nurse
10%
School of Medicine
10%
Serial Monitoring
12%
Sinai
12%
Social Rehabilitation
12%
Social Work
20%
Spinal Tumor
12%
Steady Flow
12%
Support Services
16%
Survival Benefit
10%
Symptom Burden
12%
Texas
10%
Translational Research
31%
Translational Research Programs
12%
Translational Science
10%
Treatment Efficacy
10%
Treatment Impact
12%
Treatment Options
10%
Tumor Biology
6%
Tumor Board
12%
Tumor Immunology
6%
Tumor Subtype
10%
Tumor Tissue
20%
University Health
10%
University of Kansas
12%
University of North Carolina
10%
University of South Carolina
10%
University of Utah
10%
Walter Reed
12%
Washington
10%
Medicine and Dentistry
Advanced Life Support
16%
Amlodipine Plus Olmesartan
12%
Angiogenesis Inhibitor
10%
Arm
14%
Bevacizumab
31%
Brain Tumor
100%
Cancer
10%
Cardiology
10%
Central Nervous System Tumor
36%
Clinical Research
100%
Clinical Trial
70%
Combination Therapy
10%
Consultation
10%
CTLA-4
12%
Endocrinology
10%
Glioblastoma
29%
Health System
20%
Immune Checkpoint Inhibitor
20%
Immune Response
5%
Immunocompetence
10%
Immunological Monitoring
12%
Immunoreactivity
12%
Ipilimumab
16%
Malignant Neoplasm
52%
Mediator
10%
Medical Oncology
10%
Medicine
20%
Morphology
10%
Neoplasm
72%
Neuro-Oncology
65%
Neurology
10%
Neuropathologist
24%
Neuroradiology
12%
Neurosurgery
12%
Nivolumab
16%
Nurse
10%
Nurse Practitioner
12%
Oncologist
20%
Oncology
20%
Ophthalmology
12%
Patient Care
10%
Patient Referral
20%
Peripheral Blood Mononuclear Cell
12%
Physical Medicine and Rehabilitation
20%
Placebo
17%
Psychiatry
24%
Quality of Life
10%
Radiation Oncologist
12%
Radiation Oncology
10%
Spinal Cord Tumor
12%
Symptom
10%
Symptomatic Treatment
10%
Translational Research
41%
Tumor Biology
5%
Tumor Immunology
7%